newsfilter
← Latest News
GlobeNewswire·

Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride-- Early positive trend seen in FEV1, a safety endpoint